ER-Negative Isolated Locoregional Recurrence Benefits From Chemotherapy

Breast Cancer News , Education , Featured Articles

ER-Negative Isolated Locoregional Recurrence Benefits From Chemotherapy

[ Original Article: Modern Medicine Network, Author: Dave Levitan, Feb 21 2018 ]

A final analysis of the randomized CALOR trial found that patients with estrogen receptor (ER)-negative isolated locoregional recurrence (ILRR) after unilateral breast cancer derive significant benefit from chemotherapy, while those with ER-positive disease do not.
READ MORE